Loading...
•
Jun 27
Integer Q2 2025 Earnings Report
Integer Holdings Corporation reported strong second quarter 2025 results with continued sales and profit growth.
Key Takeaways
Integer Holdings Corporation delivered a strong second quarter in 2025, with sales increasing by 11% to $476 million and adjusted EPS growing by 19% to $1.55. The company also saw a 15% increase in non-GAAP adjusted operating income, reaching $81 million. This performance led to an upward revision of the full-year adjusted operating income and EPS outlook.
Sales increased 11% to $476 million in Q2 2025, with organic growth also at 11%.
Non-GAAP adjusted EPS rose 19% to $1.55, while GAAP diluted EPS from continuing operations increased 18% to $1.04.
Non-GAAP adjusted operating income grew 15% to $81 million, and GAAP operating income increased 9% to $59 million.
The company raised its 2025 full-year adjusted operating income and EPS outlook midpoint, expecting adjusted operating income growth of 12% to 16% and adjusted EPS growth of 18% to 23%.
Integer
Integer
Integer Revenue by Segment
Revenue by Segment
Cardio & Vascular Revenue
CapyFin.comCardiac Rhythm Management & Neuromodulation Revenue
CapyFin.comOther Markets Revenue
CapyFin.com Forward Guidance
Integer Holdings Corporation is raising its 2025 full-year profit outlook, expecting continued growth in adjusted operating income and adjusted EPS.
Positive Outlook
- Expected adjusted operating income growth of 12% to 16% for the full year 2025.
- Expected adjusted EPS growth of 18% to 23% for the full year 2025.
- Anticipated GAAP sales between $1,850 million and $1,876 million, representing 8% to 9% growth.
- Projected GAAP operating income between $232 million and $244 million, an 11% to 17% increase.
- Expected cash flow from operating activities between $235 million and $255 million, a 15% to 24% increase.
Challenges Ahead
- GAAP income from continuing operations is projected to decrease by 10% to 17% ($100 million to $109 million).
- GAAP diluted earnings per share are expected to decrease by 13% to 20% ($2.79 to $3.05).
- Total debt increased by $212 million from the end of 2024, primarily due to financing acquisitions and convertible note offering costs.
- The company's complex international tax profile poses a risk.
- The healthcare industry is highly regulated and subject to various regulatory changes, which could indirectly impact the business.
Revenue & Expenses
Visualization of income flow from segment revenue to net income